Observes patient satisfaction and safety of atezolizumab in routine care
Studies how people with lung cancer or liver cancer experience atezolizumab given under the skin.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Key facts
- Where
- Krems, Linz, Vienna, and Wels, AustriaSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain lung cancers or liver cancer who are treated with atezolizumab as an injection under the skin in routine care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Early stage non-small cell lung cancer after complete surgery and platinum-based chemotherapy with a high risk of recurrence; metastatic non-small cell lung cancer; extensive-stage small cell lung cancer; or advanced or unresectable liver cancer (hepatocellular carcinoma).
- Earlier treatment
- Lung cancer and liver cancer cases must not have been treated before in the way the record describes (metastatic non-small cell lung cancer, extensive-stage small cell lung cancer: not previously treated; liver cancer: no earlier systemic therapy). No more than 4 earlier cycles of IV atezolizumab.
- Biomarker or test result
- Early stage lung cancer: PD-L1 on 50% or more of tumor cells. Metastatic lung cancer: PD-L1 on 50% or more of tumor cells or 10% or more of tumor-infiltrating immune cells. No EGFR mutation or ALK-positive lung cancer.
Main reasons for not taking part
- Not treated with atezolizumab as standard of care, in line with the approved label
- Taking other cancer medicine throughout the body at the same time as starting atezolizumab, for the same disease
- Receiving atezolizumab in a clinical trial or an early or compassionate access program
- Unwilling to fill in the questionnaires on satisfaction and quality of life
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you 18 years old or older?
- Which best describes your lung cancer?
Source: NCT07284121, who can take part
Where in Austria
- Universitatsklinikum KremsKrems, AustriaTaking people
- Ordensklinikum Linz ElisabethinenLinz, AustriaTaking people
- Krankenhaus Nord - Klinik FloridsdorfVienna, AustriaTaking people
- Klinikum Wels-GrieskirchenWels, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07284121
- Record updated
- 6 November 2026
- Original description
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.Read full original descriptionShow less
A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Inclusion: Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:; Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC; Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated; Extensive-stage small cell lung cancer (ES-SCLC) not previously treated; Advanced or unresectable HCC not previously treated with systemic therapy; Should not have received > 4 prior cycles of IV Atezolizumab.
Exclusion: Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling; Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label; Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program; Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life.